[go: up one dir, main page]

MX9304089A - Uso de gm-csf como una vacuna adyuvante. - Google Patents

Uso de gm-csf como una vacuna adyuvante.

Info

Publication number
MX9304089A
MX9304089A MX9304089A MX9304089A MX9304089A MX 9304089 A MX9304089 A MX 9304089A MX 9304089 A MX9304089 A MX 9304089A MX 9304089 A MX9304089 A MX 9304089A MX 9304089 A MX9304089 A MX 9304089A
Authority
MX
Mexico
Prior art keywords
csf
vaccine
adjuvant vaccine
mammal
effective amount
Prior art date
Application number
MX9304089A
Other languages
English (en)
Inventor
Eric M Bonnem
Imtiaz A Chaudry
Elliot Stupak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9304089A publication Critical patent/MX9304089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención es un método para realzar la respuesta inmune de un mamífero a una vacuna que consta de la administración a tal mamífero de una cantidad efectiva de GM-CSF en conjunción con una vacuna. La presente invención además proporciona una composición farmacéutica que consta de una cantidad efectiva de GM-CSF, un antígeno natural, sintético o recombinante y un transportador farmacéuticamente aceptable.
MX9304089A 1992-07-08 1993-07-07 Uso de gm-csf como una vacuna adyuvante. MX9304089A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91039992A 1992-07-08 1992-07-08

Publications (1)

Publication Number Publication Date
MX9304089A true MX9304089A (es) 1994-01-31

Family

ID=25428728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304089A MX9304089A (es) 1992-07-08 1993-07-07 Uso de gm-csf como una vacuna adyuvante.

Country Status (11)

Country Link
US (1) US5679356A (es)
EP (1) EP0651656A1 (es)
JP (1) JPH07504683A (es)
CN (1) CN1091978A (es)
AU (1) AU4662393A (es)
CA (1) CA2139756A1 (es)
IL (1) IL106280A0 (es)
MX (1) MX9304089A (es)
TN (1) TNSN93075A1 (es)
WO (1) WO1994001133A1 (es)
ZA (1) ZA934890B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
WO1995016464A1 (en) * 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
JPH09509828A (ja) * 1994-03-04 1997-10-07 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 標的遺伝子損傷をした動物
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6060258A (en) * 1995-09-28 2000-05-09 Otsuka Pharmaceutical Co., Ltd. Neutrophil chemotactic lymphokine, and method for the diagnosis of drug hypersensitive granulocytopenia using the same
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6153182A (en) * 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
ES2367625T3 (es) 1999-05-13 2011-11-07 Wyeth Holdings Corporation Formulaciones de combinaciones de adyuvantes.
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6541458B1 (en) * 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2810888B1 (fr) * 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
AU8330401A (en) * 2000-08-11 2002-02-25 Favrille Inc Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
JP2004521867A (ja) 2000-10-27 2004-07-22 イミュノ−アールエックス， インコーポレイテッド 免疫抑制された患者のためのワクチン免疫療法
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
NZ525887A (en) * 2000-11-10 2005-08-26 Wyeth Corp Adjuvant combination formulations
PE20020572A1 (es) 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
AU2002363322A1 (en) * 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
EP1374893A1 (en) * 2002-06-17 2004-01-02 NovImmune S.A. Vaccination with immuno-isolated cells producing an immunomodulator
US6809191B2 (en) * 2002-07-03 2004-10-26 Vaxim, Inc. GM-CSF nucleic acid sequences
JPWO2005034986A1 (ja) * 2003-10-14 2006-12-21 中外製薬株式会社 腎疾患治療剤
MX2007008013A (es) * 2004-12-29 2008-02-07 Mannkind Corp Metodos para producir, mejorar y sostener respuestas inmunes contra epitopos i-restringidos clase mhc por propositos profilacticos o terapeuticos.
WO2006116053A1 (en) * 2005-04-22 2006-11-02 Sciclone Pharmaceuticals, Inc. Immunomodulator compounds as vaccine enhancers
WO2007055952A2 (en) * 2005-11-03 2007-05-18 Wyeth Process for producing stable hiv th-ctl peptides
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
MX2010005718A (es) 2007-11-28 2010-08-10 Irx Therapeutics Inc Metodo para incrementar el efecto inmunologico.
US9603919B2 (en) * 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
DK2429585T3 (en) 2009-05-15 2018-07-30 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY
DK2510106T3 (en) 2009-12-08 2018-05-28 Irx Therapeutics Inc PROCEDURE FOR REVERSING IMMUNE EXPRESSION OF LANGERHANS CELLS
EA201290897A1 (ru) 2010-03-11 2013-03-29 Иммьюн Дизайн Корп. Вакцины для пандемического гриппа
CA2826920A1 (en) 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
EP2806890A4 (en) 2012-01-26 2015-09-02 Longhorn Vaccines & Diagnostics Llc COMPOSITIONAL ANTIGEN SEQUENCES AND VACCINES
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
EP4091629A1 (en) 2013-09-25 2022-11-23 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
BR112016016672A2 (pt) 2014-01-21 2017-08-08 Immune Design Corp Uso de uma composição
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
CN120514834A (zh) 2014-03-28 2025-08-22 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
US20160129098A1 (en) * 2014-11-07 2016-05-12 Wisconsin Alumni Research Foundation Targeting dna vaccines to b cells as primary antigen presenting cells
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
US11013790B2 (en) 2015-09-25 2021-05-25 Maxivax Sa Vaccination with immuno-isolated cells producing an immunomodulator
US20200115324A1 (en) 2017-06-11 2020-04-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
US20210340185A1 (en) 2018-08-29 2021-11-04 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
JP7670614B2 (ja) * 2019-01-22 2025-04-30 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 抗原提示好中球由来樹状細胞およびその使用方法
CN115551537A (zh) 2019-12-03 2022-12-30 纽沃进公司 肿瘤细胞疫苗
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
WO2021195137A1 (en) 2020-03-23 2021-09-30 Loyola University Of Chicago Coronavirus vaccine compositions and methods of using same
US12409214B2 (en) 2020-10-20 2025-09-09 Longhorn Vaccines And Diagnostics, Llc Immunogenic antigens
WO2022094391A2 (en) 2020-11-02 2022-05-05 Neuvogen, Inc. Breast cancer tumor cell vaccines
CU24734B1 (es) * 2021-03-30 2025-02-07 Ct Inmunologia Molecular Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
WO2025072659A2 (en) * 2023-09-29 2025-04-03 Partner Therapeutics, Inc. Effects of gm-csf addition on humoral modulation and fcgr2b binding in allergy, infection and immunity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
FI920131A7 (fi) * 1989-07-14 1992-01-13 American Cyanamid Co Sytokiini- ja hormonikantajia konjugaattirokotteita varten

Also Published As

Publication number Publication date
ZA934890B (en) 1994-04-14
US5679356A (en) 1997-10-21
WO1994001133A1 (en) 1994-01-20
EP0651656A1 (en) 1995-05-10
AU4662393A (en) 1994-01-31
TNSN93075A1 (fr) 1994-03-17
CA2139756A1 (en) 1994-01-20
CN1091978A (zh) 1994-09-14
IL106280A0 (en) 1993-11-15
JPH07504683A (ja) 1995-05-25

Similar Documents

Publication Publication Date Title
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
ES2092306T3 (es) Adyuvante para vacunas.
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
ES2196024T3 (es) Vacunas conjugadas de gangliosido-klh con qs-21.
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
ES8802275A1 (es) Un metodo para preparar una vacuna pra inducir inmunidad a la tosferina.
ES2061851T3 (es) Formulaciones intranasales de calcitonina.
NL300185I1 (nl) Acellulair vaccin.
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
CA2097702A1 (en) Dermatomycosis vaccine
OA09672A (en) Use of il-4 to enhance immune response to infectious antigenic challenges
MY128929A (en) Vaccine against hepatitis a and hepatitis b
IT1217314B (it) Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
AR012896A1 (es) Polipeptido flge de helicobacter pylori, composicion de vacuna, uso de dicho polipeptido para la fabricacion de composiciones, metodo de diagnostico invitro, y kit de diagnostico para la deteccion de la infeccion por helicobacter pylori
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.
ECSP972211A (es) Nueva composicion de vacuna y su uso en la medicina, especialmente para prevenir infecciones de paludismo